| gap-pubmed-20260410- | What determines the functional significance of FKBP5-HTT protein interactions? | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does FKBP5 inhibition enhance autophagy through MTOR-independent pathways? | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why are FKBP5 levels reduced in HD models and what drives this downregulation? | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do MIF-mediated ligand-receptor interactions functionally regulate EMEC meta | open | 0.81 | 0.00 | 2026-04-10 | 0 | | cancer-neurobiology |
| gap-pubmed-20260410- | What molecular mechanisms drive EMEC spatial migration from tumor periphery to c | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cancer-neurobiology |
| gap-pubmed-20260410- | How do bead density and coarsening dynamics relate to disease progression in spe | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the molecular mechanisms that initiate and drive axonal beading formati | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines KEAP1's selectivity for different reactive metabolites at distin | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does lysine 131 succinylation mechanistically activate NRF2 compared to cyst | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the safety profile and optimal dosing regimen for combined roscovitine-t | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do roscovitine and tamoxifen's different mechanisms both effectively reduce | open | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What evidence supports Cdk5 activation as THE primary cause of AD versus other e | partially_addressed | 0.91 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does cadmium-induced necroptosis occur in human neurodegeneration and other heav | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the transition from mitochondrial ROS production to necrosome as | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does cadmium specifically suppress AMPK activity to initiate the neurotoxic | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do autophagy-dependent quality-control pathways regulate microglial proteost | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the causal roles of phagocytosis in driving neurodegeneration versus be | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines when microglial phagocytosis switches from beneficial tissue rep | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the relationship between fosgonimeton's autophagy effects and its neurop | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does fosgonimeton cross the blood-brain barrier to achieve CNS effects? | resolved | 0.87 | 0.00 | 2026-04-10 | 0 | | neurotherapeutics |
| gap-pubmed-20260410- | How do accumulated oxidized lipids in TREM2-deficient microglia affect neuronal | resolved | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the downstream molecular mechanisms linking TREM2-TYROBP signaling to c | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does TREM2 loss reduce neuronal death despite impairing microglial phagocyto | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does norepinephrine loss specifically contribute to the synergistic cognitiv | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain how LC degeneration exacerbates tau pathology beyond inc | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does galantamine selectively target α-synuclein aggregates versus other misf | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the precise molecular mechanism by which α7-nAChR activation triggers au | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What structural features of rhein enable direct self-assembly into stable hydrog | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does hydrogel formation affect rhein's binding affinity and specificity for | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms enable rhein hydrogels to cross cellular membranes des | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do DNMT1-UHRF1 inhibitors show preferential cytotoxicity in cancer vs non-tr | open | 0.69 | 0.00 | 2026-04-10 | 0 | | epigenetic-therapeutics |
| gap-pubmed-20260410- | What mechanisms drive adaptive chromatin rewiring upon DNMT1 inhibition in neuro | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | To what extent does TDP-43 dysfunction causally contribute to AD pathogenesis ve | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain why AD-TDP patients have greater disease severity than A | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How should individualized treatment strategies be developed for the heterogeneou | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link MR-visible perivascular spaces to both vascular cognitive i | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do these KCNK2 genetic associations replicate across diverse populations and lar | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | How does KCNK2 rs6686529 genotype mechanistically influence antidepressant treat | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | What molecular mechanisms explain the heterosis effect of KCNK2 rs6686529 in MDD | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | What is the mechanistic relationship between circadian disruption and reduced or | open | 0.76 | 0.00 | 2026-04-10 | 0 | | circadian-neurobiology |
| gap-pubmed-20260410- | Does orexin-A manipulation directly rescue cognitive deficits and circadian dysf | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-26 | neurodegeneration |
| gap-pubmed-20260410- | How does orexin-A binding to Aβ translate from molecular inhibition to functiona | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specific tau acetylation sites that are shared between TBI a | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does S-nitrosylated GAPDH simultaneously inactivate Sirtuin1 and activate p3 | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does noradrenergic inhibition potentiate neuroinflammation without affecting | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which non-microglial cell types mediate β-adrenergic effects on AD neuroinflamma | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does β2-adrenergic receptor deletion in microglia show sex-specific effects | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does glycolytic reprogramming differentially impact microglial pro-inflammat | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms driving microglial metabolic reprogra | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |